Illustrative case study · Healthcare & Life Sciences
As AI narrows the screen, discovery spend shifts to validation.
Where to point a new production line was the decision in front of a lab consumables supplier: would AI shrink the lab work its products serve, and where? Delivered in 14 days, the report rests on 200 R&D leaders we interviewed, from discovery through QA and QC.
Illustrative example. The company, scenario, and all figures are fictional. They show UserCue’s method and deliverable format. They do not come from any client study.
The engagement
Illustrative scenariodays, with the report, the data file and a live readout.
R&D leaders who sign off on lab consumables spend.
70 discovery and 70 development leaders, plus 60 in QA and QC.
Eight categories rated shrink, hold or grow over three years, by R&D area.
A lab consumables supplier
Where to point a new production line
Capacity plan, before the build
AI-moderated interviews with category-level demand ratings
Demand by category, where freed money goes, AI adoption timing
Discovery, development and QA and QC groups in biopharma R&D
Headline figures
of discovery leaders expect validation assay use to grow as AI spreads
would put money freed by AI back into lab work, ahead of compute and software
of discovery leaders expect AI at scale within two years, against 17% in QA and QC
The question
Where should new capacity go if AI shrinks lab work?
The supplier had capital set aside for a new screening plate line, while its customers talked about AI replacing bench work. Before committing it, the product team went to the leaders who sign off on consumables spend, from discovery through QA and QC.
Where in R&D will consumables demand hold, shrink or grow as AI spreads?
Where does the money go when AI takes over bench work?
When will each R&D area use AI at scale?
What we did
How the study ran, start to finish.
- 1Kickoff
Capacity to place before the build.
Where should our new production capacity go if AI shrinks the lab work that uses our consumables? The kickoff turned it into three questions: where demand holds by R&D area, where freed money goes, and when each area adopts AI at scale.
- 2Design
Three R&D areas, a category forecast.
Every leader signs off on consumables spend for their group: 70 in discovery, 70 in development, 60 in QA and QC. Each said whether AI would shrink, hold or grow their group’s use of eight consumables categories over three years.
- 3Fielding
200 R&D leaders, in their own words.
Interviews ran by voice or text, quant and qual in one conversation, for a median 33 minutes, and closed on where each leader would send money freed by AI. The researcher read all 227 and removed 27 for contradictions or no budget authority, leaving 200.
- 4Analysis
AI shifts discovery spend to validation.
The researcher weighed every category’s ratings area by area: discovery expects money to move from primary screening into validation work, while QA and QC demand holds almost everywhere. In discovery, 61% expect screening plate use to fall and 51% expect validation assay use to grow.
- 5Readout
The new line makes validation kits.
The researcher showed the product team the demand classification by area and the spend-shift tables in a live readout, with a 37-page report and the full data file. The new capacity went to validation assay kits, starting in discovery.
What we found
Four findings from the report.
In discovery, AI moves spend toward validation: screening plate use falls while validation assay use grows. Lab work is the top use for freed money, ahead of compute and software. QA and QC demand holds in 7 of 8 categories, and discovery adopts first, with 66% of its leaders expecting AI at scale within two years.
In discovery, screening plates shrink and validation assays grow.
61% of discovery leaders expect AI to cut screening plate use over three years, and 51% expect validation assay use to grow. They say AI cuts the number of candidates a team tests but raises the proof each one needs, so spend moves to later lab work.
QA and QC demand holds almost everywhere.
Classed category by category, QA and QC demand is durable in 7 of 8 categories and at risk in none. Development holds in 6. Discovery has the most at risk: three categories, led by screening plates, with two growing and three durable.
Lab work is the top use for money freed by AI.
Asked where money freed by AI would go first, 44% of leaders put it back into lab work, ahead of compute and software (33%). Only 7% expect it returned to the budget. Discovery leaders lean furthest toward lab work, at 49%.
Where money freed by AI would go · single choice · n = 200Discovery adopts AI first, QA and QC last.
66% of discovery leaders expect AI in use at scale within two years, against 26% in development and 17% in QA and QC, where a changed method must be validated again. The shift in discovery spend is the near-term one.
AI in use at scale within two years · n = 70, 70, 60“The model tells us which twenty compounds to make. Then I spend more proving those twenty than I used to spend screening two thousand.”Discovery biology lead · Illustrative quote
Illustrative quotes
Three themes behind the numbers.
“Our primary screens are half the size they were. The plates we stopped buying went straight into cell assays.”
“Nothing AI suggests goes into release testing until we have validated it like any other method. That takes as long as it takes.”
“Whatever AI saves us at the front end, I am not handing back to finance. It pays for the experiments we never had room for.”
What the supplier did
Three moves made with the report.
Switched the planned line to validation kits.
The new line will make validation assay kits, the category 51% of discovery leaders expect to grow.
Started the rollout with discovery groups.
Supply starts where 66% expect AI at scale within two years; QA and QC accounts keep their current plan.
Held supply steady for QA and QC.
With QA and QC demand durable in 7 of 8 categories, the supplier kept those lines at full output.
Illustrative example. The company, scenario, and all figures are fictional. They show UserCue’s method and deliverable format. They do not come from any client study.
Bring us your next capacity question.
A senior researcher designs and presents every study.
Talk to our teamMore healthcare & life sciences studies